2022 Cellular Therapy Conference – Translating recent evidence on cellular therapy to real world management of malignancies

Salt Lake City, UT US
September 9, 2022 to September 10, 2022

The “2022 Cellular Therapy Conference” is a CME-accredited oncology conference being held in-person in Salt Lake City Utah. This conference features lectures and discussions with leading experts in cellular therapies. The goal of this oncology conference is to improve the knowledge, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients receiving cellular therapies for hematologic and non-hematologic disorders. The conference agenda includes an in-depth discussion and analysis of the latest scientific findings and practice-changing advances in chimeric antigen receptor (CAR) based therapies. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. 

Target Audience

  • Oncologists
  • Oncology fellows
  • Oncology nurses
  • Oncology nurse practitioners
  • Oncology physician assistants
  • Oncology pharmacists
  • Others who treat patients with hematologic malignancies and solid tumors

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical and other barriers, review strategies to navigate these factors to optimize management of patients with cellular therapies
Course summary
Available credit: 
  • 6.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.75 Contact Hours.
Course opens: 
05/24/2022
Course expires: 
10/10/2022
Event starts: 
09/09/2022 - 4:00pm PDT
Event ends: 
09/10/2022 - 3:40pm PDT
Cost:
$300.00
Add to calendar: 

Day 1 - September 09, 2022

 

4:00 PM to 4:50 PM: Registration

4:50 PM – 5:00 PM: Opening remarks

5:00 PM – 6:15 PM: Session 1 – General Concepts

5:00 PM – 5:15 PM: History of CAR-T therapy - Dr. Tania Jain

5:15 PM – 5:30 PM: CAR-T overview - Dr. Sagar Patel and Dr. Catherine Lee

5:30 PM – 5:45 PM: Barriers to CAR-T access - Dr. Navneet Majhail

5:45 PM – 6:00 PM: Academia – Community partnership - Dr. Daniel Couriel

6:00 PM – 6:15 PM: Q & A Session

 

Day 2 - September 10, 2022

 

7:00 AM – 8:00 AM: Registration

8:00 AM – 8:15 AM: Opening remarks

8:15 AM – 9:15 AM: Session 2 – CLL/NHL

8:15 AM – 8:30 AM: CAR- T in CLL - Dr. Harsh Shah

8:30 AM – 8:45 AM: CAR-T in B-NHL - Dr. Boyu Hu

8:45 AM – 9:00 AM: CAR-T in indolent lymphomas - Dr. Daniel Ermann

9:00 AM – 9:15 AM: Q & A Session

9:15 AM – 10:15 AM: Session 3 - ALL

9:15 AM – 9:35 AM: CAR-T in pediatric B-ALL - Dr. Michael Pulsipher

9:35 AM – 9:55 AM: CAR-T in adult B-ALL - Dr. Nitin Jain

9:55 AM – 10:15 AM: Q & A Session

10:15 AM – 11:00 AM: Break

11:00 AM – 12:00 PM: Session 4 – Special topics

11:00 AM – 11:15 AM: CAR-T in high-risk populations - Dr. Brad Hunter

11:15 AM – 11:30 AM: The role of radiation in CAR-T - Dr. Randa Tao

11:30 AM – 11:45 AM: COVID-19 and CAR-T - Dr. Hannah Imlay

11:45 AM – 12:00 PM: Q & A Session

12:00 PM – 01:00 PM: Lunch

1:00 PM – 2:00 PM: Session 5 – Multiple myeloma

1:00 PM – 1:20 PM: CAR-T in multiple myeloma - Dr. Brian McClune

1:20 PM – 1:40 PM: Emerging cellular therapies in multiple myeloma - Dr. Douglas Sborov

1:40 PM – 2:00 PM: Q & A Session

2:00 PM – 3:00 PM: Session 6 – Solid tumors

2:00 PM – 2:20 PM: CAR-T in PCNSL and SCNSL - Dr. P. Connor Johnson

2:20 PM – 2:40 PM: CAR-T in solid tumors - Dr. Umang Swami

2:40 PM – 3:00 PM: Q & A Session

3:00 PM – 4:00 PM: Session 7 – Supportive care

3:00 PM – 3:20 AM: CAR-T Toxicity management - Angela Kirk, PA-C

3:20 AM – 3:40 AM: Infectious complications in CAR-T - Dr. Carlos Gomez

3:40 PM – 4:00 PM: Q & A Session

4:00 PM: Closing remarks/Adjourn

Hilton Salt Lake City Center
255 SW Temple
Salt Lake City, UT 84101
United States

A limited number of rooms have been reserved for the attendees of this conference at the Hilton Salt Lake City Center at the discounted rate of $169 per night. All reservations must be made by Monday, August 8, 2022 to receive the discounted rate. Please follow the link below to reserve your room: https://book.passkey.com/e/50341396

Overnight self-parking is complimentary to hotel guests.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Speaker/Topic Presenter(s)

Daniel Couriel, MD, MS, MBA

has a financial relationship (Professional Services) with Incyte, Inc;.
has a financial relationship (Other) with Seagen, Inc;.

Daniel Ermann, Medical Doctor

has no relevant financial relationships to disclose at this time.

Carlos Gomez, MD

has no relevant financial relationships to disclose at this time.

Boyu Hu

has a financial relationship (Other) with TG Therapeutics;.
has a financial relationship (Other) with Bristol Meyer Squibb;.
has a financial relationship (Grant Or Contract) with Morphosys Ag;.
has a financial relationship (Other) with MJH Life Sciences;.
has a financial relationship (Grant Or Contract) with CRISPR Therapeutics;.
has a financial relationship (Grant Or Contract) with Caribou Biosciences;.
has a financial relationship (Other) with OncLive;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with ADC Therapeutics;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Repare Therapeutics;.

Bradley Hunter, MD. MPH

has a financial relationship (Professional Services) with Kite Pharma;.
has a financial relationship (Professional Services) with Notable Labs;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Novartis;.

Hannah Imlay

has no relevant financial relationships to disclose at this time.

Nitin Jain, MD

has a financial relationship (Gift) with Genentech;.
has a financial relationship (Gift) with Beigene;.
has a financial relationship (Gift) with AbbVie;.
has a financial relationship (Gift) with Precision Bio;.
has a financial relationship (Gift) with Janssen;.
has a financial relationship (Gift) with Kite;.
has a financial relationship (Gift) with Fate Therapeutics;.
has a financial relationship (Gift) with Pharmacyclics;.
has a financial relationship (Gift) with AstraZeneca;.
has a financial relationship (Gift) with Cellectis;.

Tania Jain, MBBS

has a financial relationship (Other) with CTI Biopharma, SyneosHealth, Incyte;.
has a financial relationship (Other) with Care Dx, Bristol Myers Squibb, Incyte, Abbvie, CTI, and Kite;.

Patrick Johnson, MD

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with ADC Therapeutics;.
has a financial relationship (Independent contractor) with Seagen;.

Angela Kirk, Physician Assistant

has no relevant financial relationships to disclose at this time.

Catherine Lee, MD

has a financial relationship (Independent contractor) with Kadmon;.
has a financial relationship (Grant Or Contract) with Incyte Corporation;.
has a financial relationship (Independent contractor) with Jazz Pharmaceuticals;.
has a financial relationship (Independent contractor) with Fresenius Kabi;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Stock) with Kadmon;.

Navneet Majhail, MD, MS, FASTCT

has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Anthem Inc;.

Brian McClune, DO

has no relevant financial relationships to disclose at this time.

Sagar Patel, MD

has a financial relationship (Grant Or Contract) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with Medexus;.
has a financial relationship (Grant Or Contract) with CareDx;.

Michael Pulsipher

has a financial relationship (Other) with Bluebird;.
has a financial relationship (Other) with Gentibio;.
has a financial relationship (Other) with Equillium;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Medexus;.
has a financial relationship (Other) with Vertex;.

Douglas Sborov, MD MS

has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Abbvie;.

Harsh Shah, D.O.

has a financial relationship (Grant Or Contract) with BeiGene;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.

Umang Swami, MD, MS

has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Seattle Genetics;.
has a financial relationship (Other) with Exelixis;.

Randa Tao, MD

has a financial relationship (Travel) with The Lynx Group;.
has a financial relationship (Other) with QED Therapeutics;.
has a financial relationship (Other) with Helsinn;.
Planning committee(s)

Catherine Lee, MD

has a financial relationship (Independent contractor) with Fresenius Kabi;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Stock) with Kadmon;.
has a financial relationship (Grant Or Contract) with Incyte Corporation;.
has a financial relationship (Independent contractor) with Kadmon;.
has a financial relationship (Independent contractor) with Jazz Pharmaceuticals;.

Sagar Patel, MD

has a financial relationship (Grant Or Contract) with Medexus;.
has a financial relationship (Grant Or Contract) with CareDx;.
has a financial relationship (Grant Or Contract) with Kite Pharma;.

Available Credit

  • 6.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.75 Contact Hours.

Price

Cost:
$300.00
Please login or register to take this course.

Early-bird registration ends August 7th, 2022.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $200

Fellows & residents - $150

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.